Evidence map›Paper›PMID 29382825›Full record

ArticleTranslational psychiatry2018

Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects.

Caterina Scuderi, Maria Rosanna Bronzuoli, Roberta Facchinetti, Lorenzo Pace, Luca Ferraro, Kevin Donald Broad, Gaetano Serviddio, Francesco Bellanti, Gianmauro Palombelli, Giulia Carpinelli and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 4 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 4 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. A systematic review of treatment for patients with burning mouth syndrome.Cephalalgia : an international journal of headache · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Palmitoylethanolamide in Human and Animal Obesity.Molecules (Basel, Switzerland) · 2026
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Chronic palmitoylethanolamide administrationFrontiers in cellular neuroscience · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Caterina ScuderiDepartment of Physiology and Pharmacology "V. Erspamer", SAPIENZA University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-7314-1539
Maria Rosanna BronzuoliDepartment of Physiology and Pharmacology "V. Erspamer", SAPIENZA University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0002-5022-8295
Roberta FacchinettiDepartment of Physiology and Pharmacology "V. Erspamer", SAPIENZA University of Rome, Rome, Italy.ORCID http://orcid.org/0000-0003-3452-2272
Lorenzo PaceDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Luca FerraroDepartment of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
Kevin Donald BroadUCL Institute of Opthalmology, University College, University College London, London, UK.
Gaetano ServiddioC.U.R.E. Centre for Liver Diseases Research and Treatment, Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Francesco BellantiC.U.R.E. Centre for Liver Diseases Research and Treatment, Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Gianmauro PalombelliDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.
Giulia CarpinelliDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.
Rossella CaneseDepartment of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.
Silvana GaetaniDepartment of Physiology and Pharmacology "V. Erspamer", SAPIENZA University of Rome, Rome, Italy.
Luca SteardoDepartment of Psychiatry, University of Naples SUN, Naples, Italy.ORCID http://orcid.org/0000-0002-7077-3506
Luca SteardoDepartment of Physiology and Pharmacology "V. Erspamer", SAPIENZA University of Rome, Rome, Italy. luca.steardo@uniroma1.it.ORCID http://orcid.org/0000-0003-3570-2195
Tommaso CassanoDepartment of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy.
Sapienza University of Rome · ITUniversity of Foggia · ITIstituto Superiore di Sanità · ITUniversity of Naples Federico II · ITUniversity College London · GBUniversity of Ferrara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In an aging society, Alzheimer's disease (AD) exerts an increasingly serious health and economic burden. Current treatments provide inadequate symptomatic relief as several distinct pathological processes are thought to underlie the decline of cognitive and neural function seen in AD. This suggests that the efficacy of treatment requires a multitargeted approach. In this context, palmitoylethanolamide (PEA) provides a novel potential adjunct therapy that can be incorporated into a multitargeted treatment strategy. We used young (6-month-old) and adult (12-month-old) 3×Tg-AD mice that received ultramicronized PEA (um-PEA) for 3 months via a subcutaneous delivery system. Mice were tested with a range of cognitive and noncognitive tasks, scanned with magnetic resonance imaging/magnetic resonance spectroscopy (MRI/MRS), and neurochemical release was assessed by microdialysis. Potential neuropathological mechanisms were assessed postmortem by western blot, reverse transcription-polymerase chain reaction (RT-PCR), and immunofluorescence. Our data demonstrate that um-PEA improves learning and memory, and ameliorates both the depressive and anhedonia-like phenotype of 3×Tg-AD mice. Moreover, it reduces Aβ formation, the phosphorylation of tau proteins, and promotes neuronal survival in the CA1 subregion of the hippocampus. Finally, um-PEA normalizes astrocytic function, rebalances glutamatergic transmission, and restrains neuroinflammation. The efficacy of um-PEA is particularly potent in younger mice, suggesting its potential as an early treatment. These data demonstrate that um-PEA is a novel and effective promising treatment for AD with the potential to be integrated into a multitargeted treatment strategy in combination with other drugs. Um-PEA is already registered for human use. This, in combination with our data, suggests the potential to rapidly proceed to clinical use.

Indexed as

Age FactorsAlzheimer DiseaseAmidesAmyloid beta-PeptidesAnimalsAnti-Inflammatory AgentsBehavior, AnimalCA1 Region, HippocampalCognitive DysfunctionDisease Models, AnimalEthanolaminesInflammationLearningMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMaleAmidesAmyloid beta-PeptidesAnti-Inflammatory AgentsEthanolaminesNeuroprotective AgentspalmidrolPalmitic Acidstau Proteins

Identifiers

PMID29382825
PMCPMC5802581
OpenAlexW2788331446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.